Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1/PD-L1 inhibitor failure: a retrospective multicenter study
Cadonilimab might offer a promising option with a manageable safety profile for patients with R/M CC who progress after ICI treatment. Further studies with larger sample sizes are needed to confirm these findings.
Authors
- Ning Xie (ORCID: https://orcid.org/0009-0003-4506-3478)
- Linying Liu
- Haijuan Yu
- Lijun Chen (ORCID: https://orcid.org/0000-0002-6048-7434)
- Sufang Deng
- Jian Chen
- Jianping Zou
- Jie Lin
- Yang Sun
- Bin Liu
Institutions
- Fujian Medical University (CN)
- Ministry of Education of the People's Republic of China (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1701319
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00